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IV phenobarbitone shock
To the Editor: It has been brought to the attention of the 
Executive Committee of the South African Paediatric 
Association that the intravenous form of phenobarbitone is no 
longer available in South Africa.
   In August 2004 Aventis informed all provincial authorities 
that the worldwide production of sodium gardenal would be 
stopped and that it would no longer be available once stocks 
had been depleted. 
   This is a matter of great concern in terms of treating children 
in South Africa, especially those who present with epilepsy, in 
particular status epilepticus. In general, as far as developing 
countries are concerned, the action of Aventis cannot be 
defended. It would have been far better had they made sure 
that alternative arrangements were available in Africa before 
unilaterally withdrawing sodium gardenal.
   Intravenous phenobarbitone has proved to be highly 
effective, it is safe and cheap, it can be given in repeated 
doses by rapid push-in, and it is currently recommended 
on all the international APLS guidelines for the treatment of 
status epilepticus. We have been informed that intravenous 
phenytoin or lorazepam are proposed alternatives. These drugs 
would not pose a problem in tertiary settings, but at primary 
and secondary level intravenous phenobarbitone is easy to 
administer with relatively few complications, and needs to be 
available.
   The decision by the World Health Organization (WHO) 
to remove intravenous phenobarbitone extensively without 
consultation in developing countries, especially in Africa, is 
also disconcerting. It is strongly advised that this matter be 
reconsidered and that dialogue be initiated with the WHO on 
this issue.
   Phenytoin and lorazepam have been suggested as 
alternatives. Intravenous phenytoin has to be administered 
over a long period of time via a syringe driver and requires 
an intravenous line, which may not always be possible in 
rural settings. Cardiac monitoring is recommended because of 
cardiac arrhythmias. It cannot be repeated once given and it 
may not be as affective as phenobarbitone.
   Lorazepam, on the other hand, is dangerous as a follow-
up after 2 doses of short-acting benzodiazepine because 
respiratory depression is very likely. Again, this would be a 
problem in primary and secondary settings where there are 
no facilities to ventilate children. It is also markedly expensive 
compared with intravenous phenobarbitone.
   It is therefore clear that intravenous phenobarbitone remains 
the mainstay of first-line treatment for status epilepticus, 
especially in the primary and secondary health care settings, 
where the majority of children in South Africa are managed. 
Phenobarbitone is still manufactured by alternative companies 
internationally and we would support efforts to have these 
products registered and distributed in South Africa as soon as 
possible.
   Currently intravenous phenobarbitone is available as a Sec- 
tion 21 medication, but this is not effective or useful for the fut- 
ure use of intravenous phenobarbitone for the children at risk.
   We urge the Department of Health to take cognisance of the 
problem, and we would support any initiative from the Central 
Department of Health to address this medical crisis in the 
management of status epilepticus in children.
Raziya Bobat
On behalf of the South African Paediatric Association Executive 
Committee
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‘Found guilty’ – an unjust outcome?
To the Editor: A well-respected surgical colleague was recently 
found guilty by the Health Professions Council of South 
Africa (HPCSA) on 5 of 8 charges after complications arose 
from a laparoscopic procedure for gastric reflux. Sentence was 
delivered on Friday 14 October, where he was cautioned and 
discharged.
   As an anaesthesiologist I have witnessed many of these 
procedures by a wide variety of surgeons and my comments 
are based on personal experience.  Looking at those who 
made up the bench for this hearing (a general practitioner, 
a community medicine doctor and a retired surgeon), I’m 
surprised that they did not include a surgeon actively involved 
in this type of surgery. 
    Together with all my colleagues currently engaged in 
laparoscopic surgery in Cape Town, I am devastated by 
the outcome of the hearing. Knowing what happened, and 
the steps taken to manage events, we can only assume that 
inexperienced people are, unfairly to themselves, being 
appointed to sit at these hearings.
   The complications that arose in this case are well known 
to those involved in laparoscopic surgery. There is nothing 
disgraceful about a wrong clinical decision … it is human. 
The unfortunate surgeon, who is highly experienced in 
laparoscopic surgery and well respected by colleagues, 
both academic and private, acted in the best interests of the 
patient. He sought advice and the problem was eventually 
resolved. The patient had a traumatic postoperative course but 
fortunately survived the ordeal and I believe is now fit and 
healthy. I have a sneaking suspicion that this case represents an 
attack on laparoscopic surgery by those who seem to have very 
little insight into the specialty.
   A surgeon’s decision may not always be correct, but to be 
found guilty of unprofessional conduct and to be accused of 
belated surgical action, failing to recognise the clinical course 
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